LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product candidate is LB-102, a small molecule oral product currently in Phase 3 clinical trials for the treatment of acute schizophrenia. The company also has a completed Phase 2 clinical trial for LB-102 in bipolar I depression and adjunctive treatment of major depressive disorder (MDD), as well as a preclinical-stage long-acting injectable (LAI) formulation. LB Pharmaceuticals aims to address unmet medical needs in neuropsychiatry by advancing innovative treatments through clinical development.

LB Pharmaceuticals Inc is listed on the Nasdaq Capital Market (NasdaqGM) under the ticker symbol LBRX. Its shares are traded in US Dollars (USD), which is the standard currency for equities listed on US exchanges. The company is headquartered in New York, New York, and operates within the United States healthcare sector.

LB Pharmaceuticals Inc operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel therapies for neurological and psychiatric conditions. The company's work involves clinical-stage drug development, leveraging scientific expertise to create treatments for diseases such as schizophrenia and bipolar depression.

LB Pharmaceuticals Inc is headquartered in New York, New York, United States. The company primarily serves the US market, as indicated by its region classification as 'us'. Its clinical trials and regulatory activities are focused on the US healthcare system, targeting approval and commercialization of its therapies for neuropsychiatric diseases within the United States.

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that generates value through the research and development of novel therapies for neuropsychiatric disorders. Its business model involves advancing drug candidates through clinical trials to obtain regulatory approval and ultimately commercialize them. The company's lead asset is LB-102, an oral small molecule in Phase 3 trials for acute schizophrenia. Additionally, LB-102 has completed Phase 2 trials for bipolar I depression and adjunctive treatment of major depressive disorder (MDD). The company also has a preclinical long-acting injectable (LAI) formulation in its pipeline. LB Pharmaceuticals does not yet have approved products or reported revenues, as it is still in the development stage.